[1]Jin S,Li M,Fang Y,et al.Chinese Registry of rheumatoid arthritis (CREDIT):II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis[J].Arthritis Research & Therapy,2017,19(1):251.[2]Yu C, Li M, Duan X, et al.Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis[J].Clin Exp Rheumatol,2018,36(5):836-840.[3]風溼免疫疾病慢病管理全國護理協作組. 類風溼關節炎患者的慢病管理專家共識（2014 版）[J].中華風溼病學雜誌,2016,20(2):127-131.[4]Bakker MF,Jacobs JW,Welsing PM,et al.Early clinical response to treatment predicts 5-year outcome in RA patients:follow-up results from the CAMERA study[J]. Ann Rheum Dis,2011,70(6):1099-103.[5]楊陽,李曉軍. 類風溼關節炎生物標誌物研究進展: 從蛋白質到非編碼RNA[J]. 臨牀檢驗雜誌,2017,35(1):1-4.[6]Carretero G,Puig L,Carrascosa JM,et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy[J].J Dermatolog Treat,2018, 29(4):334-346.[7]Hernandez MV,Sanchez-Piedra C,Garcia-Magallon B,et al. Factors associated with long-term retention of treatment with golimumab in a real-world setting:an analysis of the Spanish BIOBADASER registry[J].Rheumatol Int,2019,39(3):509-515. [8]Dalén J,Svedbom A,Black CM,et al.Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence[J].Rheumatol Int,2016, 36(7):987-95. [9]Schiff M,Keiserman M,Codding C,et al.Efficacy and safety of abatacept or infliximab vs placebo in ATTEST:a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate[J].Ann Rheum Dis,2008,67(8):1096-1103.[10]Weinblatt ME,Schiff M,Valente R,et al.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study[J].Arthritis Rheum,2013, 65(1):28-38.[11]Schiff M,Weinblatt ME,Valente R,et al.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial[J].Ann Rheum Dis,2014,73(1):86-94. [12]Bathon J,Robles M,Ximenes AC,et al.Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes[J]. Ann Rheum Dis,2011,70(11):1949-56. [13]Kremer JM,Peterfy C,Russell AS,et al.Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial[J].J Rheumatol,2014,41(6):1077-87.[14]Gottenberg JE,Courvoisier DS,Hernandez MV,et al. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis[J].Arthritis Rheumatol,2016, 68(6):1346-52. [15]Fleischmann R,Weinblatt M,Ahmad H,et al.Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)[J].Rheumatol Ther,2019, 6(4):559-571. [16]Harrold LR,Litman HJ,Connolly SE,et al.Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study[J].J Rheumatol,2018,45(1):32-39.[17]Okazaki S,Watanabe R,Harigae H,et al.Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis[J].Tohoku J Exp Med,2020,250(3):153-159. [18]Takemoto T,Takahashi N,Kida D,et al. Improvement in matrix metalloproteinase-3 independently predicts low disease activity at 52 weeks in bio-switch rheumatoid arthritis patients treated with abatacept[J].Clin Exp Rheumatol,2020,38(5):933-939.[19]Chen SK,Liao KP,Liu J,et al.Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study[J].Arthritis Care Res (Hoboken),2020,72(1):9-17. [20]Kremer JM, Dougados M, Emery P, et al.Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial[J]. Arthritis Rheum,2005, 52(8):2263-2271.[21]Westhovens R,Kremer JM,Emery P,et al.Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study[J]. Clin Exp Rheumatol, 2014, 32(4):553-562.[22]Padovan M,Filippini M,Tincani A,et al.Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection[J]. Arthritis Care Res (Hoboken), 2016,68(6):738-743.[23]Peichl P, Alten R, Galeazzi M, et al. Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study[J]. Wien Med Wochenschr,2020,170(5-6):132-140. [24]Karpes Matusevich AR,Duan Z,Zhao H,et al.Treatment sequences after discontinuing a tumor necrosis factor inhibitor in patients with rheumatoid arthritis. A comparison of cycling versus swapping strategies[J].Arthritis Care Res (Hoboken). 2020. doi: 10.1002/acr.24358. [25]Schäfer M,Meißner Y,Kekow J,et al.Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis[J].Rheumatology (Oxford),2020,59(8):1916-1926. [26]Ito H,Tsuji S,Nakayama M,et al.Does Abatacept Increase Postoperative Adverse Events in Rheumatoid Arthritis Compared with Conventional Synthetic Disease-modifying Drugs[J].J Rheumatol,2020,47(4):502-509.[27]Sekiguchi M,Fujii T,Matsui K,et al. Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD Study[J].J Rheumatol,2016,43(11):197.[28]Takahashi N,Kojima T,Asai S,et al.Being elderly is not a predictive factor of discontinuation of abatacept due to adverse events in rheumatoid arthritis patients with concomitant methotrexate: a retrospective observational study based on data from a Japanese multicenter registry study [abstract].Arthritis Rheumatol,2017,69:4–83.[29]Muraoka S,Yamada Z,Hirose W, et al. Comparison of the efficacy of abatacept on elderly and young patients with rheumatoid arthritis[J].Ann Rheum Dis,2020,79:988.
